The Next Generation of NGS; What's Missing and What's NextWednesday, 4 September 2013 at 16:35  Add to Calendar ▼2013-09-04 16:35:002013-09-04 17:35:00Europe/LondonThe Next Generation of NGS; What's Missing and What's Next Molecular Medicine Congress in Frankfurt, GermanyFrankfurt, GermanySELECTBIOenquiries@selectbiosciences.comThe DNA sequencing field has seen dramatic advances since the first draft of the human genome was published, with companies reporting ever faster and cheaper methods. However, despite the race to attain the $1000 genome producing a plethora of exciting technologies, CE is still being routinely used for targeted clinical sequencing for genetic testing and drug resistance testing for infectious disease. QuantuMDx is developing two sequencing technologies to address this; a portable, handheld DNA sequencing device for PGx and infectious disease applications, to provide an alternative to slow and relatively expensive CE DNA sequencing and a "LastGen 2.0" technology to take on Nanopore sequencing head on, dubbed, T2T (Telomere to Telomere). The Next Generation of NGS; What's Missing and What's NextWednesday, 4 September 2013 at 14:15 Add to Calendar ▼2013-09-04 16:35:002013-09-04 17:35:00Europe/LondonThe Next Generation of NGS; What's Missing and What's Next Molecular Medicine Congress in Frankfurt, GermanyFrankfurt, GermanySELECTBIOenquiries@selectbiosciences.comThe DNA sequencing field has seen dramatic advances since the first draft of the human genome was published, with companies reporting ever faster and cheaper methods. However, despite the race to attain the $1000 genome producing a plethora of exciting technologies, CE is still being routinely used for targeted clinical sequencing for genetic testing and drug resistance testing for infectious disease. NGS, third generation and even "LastGen" offer much promise for the future of genomics, but their translation into the clinic. QuantuMDx is developing two sequencing technologies to address this; a portable, handheld DNA sequencing device for PGx and infectious disease applications, to provide an alternative to slow and relatively expensive CE DNA sequencing and a "LastGen 2.0" technology to take on Nanopore sequencing head on, dubbed, T2T (Telomere to Telomere). The Next Generation of NGS; What's Missing and What's NextWednesday, 4 September 2013 at 14:15 Add to Calendar ▼2013-09-04 16:35:002013-09-04 17:35:00Europe/LondonThe Next Generation of NGS; What's Missing and What's Next Molecular Medicine Congress in Frankfurt, GermanyFrankfurt, GermanySELECTBIOenquiries@selectbiosciences.comThe DNA sequencing field has seen dramatic advances since the first draft of the human genome was published, with companies reporting ever faster and cheaper methods. However, despite the race to attain the $1000 genome producing a plethora of exciting technologies, CE is still being routinely used for targeted clinical sequencing for genetic testing and drug resistance testing for infectious disease. NGS, third generation and even "LastGen" offer much promise for the future of genomics, but their translation into the clinic. QuantuMDx is developing two sequencing technologies to address this; a portable, handheld DNA sequencing device for PGx and infectious disease applications, to provide an alternative to slow and relatively expensive CE DNA sequencing and a "LastGen 2.0" technology to take on Nanopore sequencing head on, dubbed, T2T (Telomere to Telomere). |
Add to Calendar ▼2013-09-03 00:00:002013-09-04 00:00:00Europe/LondonMolecular Medicine CongressMolecular Medicine Congress in Frankfurt, GermanyFrankfurt, GermanySELECTBIOenquiries@selectbiosciences.com
